Wedbush Securities’s Kiora Pharmaceuticals KPRX Stock Holding History

Wedbush Securities’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3	Closed	-$4K	–	1007
2019 Q2	$4K	Hold	3	–	–	﹤0.01%	981
2019 Q1	$5K	Sell	3 -1	-25%	-$2.43K	﹤0.01%	923
2018 Q4	$9K	Hold	4	–	–	﹤0.01%	826
2018 Q3	$6K	Hold	4	–	–	﹤0.01%	896
2018 Q2	$11K	Hold	4	–	–	﹤0.01%	874
2018 Q1	$8K	Hold	4	–	–	﹤0.01%	813
2017 Q4	$21K	Buy	+4	New	+$24.7K	﹤0.01%	842

Other funds holding KPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wedbush Securities's KPRX Position: Q3 2019 in Review

Wedbush Securities sold out of Kiora Pharmaceuticals (KPRX) in Q3 2019, closing a stake of 3 shares — an estimated $4K sold.

Wedbush Securities first reported a position in KPRX in Q4 2017 and held it in 7 quarters. The position peaked at $21K in Q4 2017. 9 funds tracked by Wall St. Rank hold KPRX as of Q3 2019.

Wedbush Securities reported no remaining Kiora Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Wedbush Securities sold 3 Kiora Pharmaceuticals shares in Q3 2019, an estimated $4K.
Wedbush Securities first reported a position in Kiora Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Wedbush Securities's Kiora Pharmaceuticals position peaked at $21K in Q4 2017.
9 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.